



**Oregon State
University**

Carlson College of Veterinary Medicine

cvmresearch@oregonstate.edu

RESEARCH RELATED TOPICS
NOVEMBER 2018 EDITION

Biomedical Sciences Seminar Series

Tuesday, November 6, 2018

Tuesday, November 6, 2018, 12:00-1:00pm, Magruder 102, OSU India Summer Research Students, Leslie Cohen, Lisa Augustine, Kaitlin Esson, Jean-Paul Reboulet, John Klein, Sarah Pope, Alexandra Hoff, Amanda Denninger, "Exploring Cultural Variations in Veterinary Medicine in Bangalore, India".

Tuesday, November 13, 2018

Tuesday, November 13, 2018, 12:00-1:00pm, Magruder 102, Caroline L. Ng, Ph.D., "TBA".

Tuesday, November 27, 2018

Tuesday, November 27, 2018, 12:00-1:00pm, Magruder 102, Farooq Azam, Ph.D., "TBA".

Biochemistry and Biophysics Seminar Series

Wednesday, November 14, 2018

Wednesday, November 14, 2018 at 3pm in ALS 4001, Dr. Dorothy Beckett, University of Maryland, "Disorder-to-order Transitions and Residue Networks in Protein Allostery".

Wednesday, November 28, 2018

Wednesday, November 28, 2018 at 3pm in ALS 4001, Dr. Rebecca Page, University of Arizona, "Cracking the Phosphatase Code: Connecting Structure with Biology to Understand the Regulation of Phosphorylation".

College of Public Health & Human Sciences Seminar Series

All seminars are 1:00 – 2:00 pm, Tammy Bray Leadership Conference Room (Hallie Ford Center #115).

Friday, November 9, 2018.

Alyshia Galvez, Ph.D. Professor of Latin American and Latino Studies, Lehman College of the City University of New York, "Eating NAFTA: Trade, Food Policies, and the Destruction of Mexico".

Friday, November 16, 2018

David Rothwell, Ph.D., MSW, Assistant Professor in Human Development and Family Sciences, CPHHS, "The Oregon Poverty Measure: Creation and Preliminary Findings".

Friday, November 30, 2018

Carol Ryff, Ph.D., Professor, Department of Psychology, Director of the Institute on Aging, University of Wisconsin, Madison, "Rethinking the Meaning of Human Health: Transformational Advances from MIDUS".

Upcoming Funding Deadlines

LOI Deadline October 30, 2018

PAR-18-880 NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)

Letter of Intent Due Date(s) 30 days prior to the application due date(October 30, 2018).

Application Due Date(s) November 2, 2018, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on this date.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **AIDS Application Due Date(s) Not Applicable.**

<http://grants.nih.gov/grants/guide/pa-files/PAR-18-880.html>

Announcement Type Reissue of [PAR-17-494](#).

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/Pis) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research

Deadline November 1, 2018

Spencer Organization - Small Research Grants Program

<https://www.pep-net.org/spencer-foundation-small-research-grants-program>

Deadlines: Small Research Grant proposals are accepted 4 times per year. The next deadline is at 4:00pm CDT, May 1, 2018. The following deadlines will fall on **November 1, 2018, and February 1, 2019.**

<https://www.spencer.org/small-research-grants>

The Small Research Grants program aims to support smaller scale or pilot research projects that have budgets of \$50,000 or less. Proposals are encouraged from scholars across a variety of disciplines in an effort to fund field-initiated education research.

In September 2017, ahead of the November deadline, we hosted an informational webinar in which we gave an overview of the program and proposal submission process. You can access the slides from the webinar and a recording of the webinar itself below, but please note that the dates mentioned are no longer applicable and the online application has been slightly updated.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 1, 2018

Alex's Lemonade Stand Foundation - 2019 Innovation Grants

<https://www.alexlemonade.org/researchers-reviewers/applicants>

The Innovation Grant is designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. Proposals should have clinical translation in view. \$250,000. Requires letter of Intent.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 1, 2018

American Quarter Horse Foundation - Equine Drug Testing

<https://www.aqha.com/foundation/pages/wwwaqhacomresearchapplication/>

In order to identify varying pharmaceutical agents, hormones, nutrients and or toxins administered for the purpose of performance enhancement, research in the areas of pharmacology, toxicology, pharmacokinetics, pharmacodynamics and related testing procedures are being solicited by AQHA. Amount of funding varies. The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 1, 2018

American Quarter Horse Foundation - Equine Research

<https://www.aqha.com/foundation/pages/wwwaqhacomresearchapplication/>

The American Quarter Horse Foundation encourages the submission of research projects related to the health, welfare and utility of the horse that will create meaningful impact for the horse, horse owners and the equine industry.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 1, 2018

American Quarter Horse Foundation – Refrigerator Fund for Equine Head Trauma

<https://equusmagazine.com/blog-equus/aqha-foundations-refrigerator-fund-will-support-research-on-head-trauma-injuries-in-horses>

This fund was created in memory of the award-winning racing horse “Refrigerator” who passed due to complications of a head trauma injury. Targeted research directed at prevention, treatment, diagnostics and hospitalization or prognosis is desired, including evaluation, comparison, management and historical or retrospective analysis. Special consideration will be given to projects with a collaborative approach between departments and or institutions. Award amount varies.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 1, 2018

Foundation for Physical Medicine & Rehabilitation - Mid-Career Research Grant

<http://foundationforpmr.org/research-grants-2/>

Through the program, a single grant of \$20,000 will be awarded to a research project in the area of physical medicine and rehabilitation by an established investigator with a track record of success. The annual award aims to allow the researcher to extend his/her work in a new direction.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 6, 2018

RFA-DK-18-002 Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-002.html>

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) December 6, 2018, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.

Deadline November 7, 2018

VentureWell

<https://venturewell.org/facultygrants/>

Faculty Grants Grants will be awarded to help fund and support faculty with innovative ideas to create new or transform existing courses and programs to help students develop novel, STEM-based inventions and gain the necessary entrepreneurial skills needed to bring these ideas to market. Successful proposals include: a focus on technology entrepreneurship; experiential learning; formation of student teams focused on inventions with positive social and/or environmental impact; support for teams to pursue commercialization; a plan for program continuation after grant period. \$30,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 7, 2018

DeGregorio Family Foundation for Gastric and Esophageal Cancer

<http://www.degregorio.org/our-research/funded-research.html>

Research Proposals Grants of up to \$250,000 will be awarded in support of innovative, high-quality translational and bench research that improves the understanding of the biology of these diseases, identification of potential novel therapeutic targets, and/or the development and evaluation of novel biomarkers for early diagnosis and treatment. Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies, and epidemiologic studies are eligible for support.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 7, 2018

NSF 17-573 Advancing Informal STEM Learning (AISL)

[NSF Advanced Informal STEM Learning \(AISL\)](#)

Next due dates are: November 07, 2018, November 06, 2019.

NSF 17-573 - NSF Advanced Informal STEM Learning (AISL) is now limited. See below.

Please note changes: The number of proposals for which an organization may be the lead is limited to three (3); and The number of proposals for which one can be PI/Co-PI is limited to three (3); and The minimum one-year budget amount is \$75,000 for an organization in collaborative proposals uploaded as separate submissions from multiple organizations. Interested - please email research.development@oregonstate.edu.

Deadline November 9, 2018

Oregon Dairy Farmers Association RFP - Nov 9 due date

The Oregon Dairy Farmers Association (ODFA) has released its RFP for 2019 funding – see attached or <http://agresearchfoundation.oregonstate.edu/funding-opportunities>

\$75,000 in funding is available. Areas of interest include the following:

Projects that are related to enhancing profitability and sustainability of dairy operations in Oregon through:

1. Air quality (e.g. odor; feed storage and management; etc.)
2. Animal welfare and employee protocols
3. Water use/irrigation management and technologies
4. Enhancement of quality and production of forages
5. Animal disease and health
6. Improved farm protocols to increase milk quality
7. Manure management/nitrogen efficiency and management (e.g. odor; composting; etc.)
8. Pasture management improvements
9. Improvement in reproductive efficiency
10. Feed efficiency

Contact the ARF office for questions about the application process. Contact ODFA Executive Director Tami Kerr about research priorities - tami.kerr@oregondairyfarmers.org <<mailto:tami.kerr@oregondairyfarmers.org>>

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 9, 2018

Woodrow Wilson National Fellowship Foundation - Course Hero-Woodrow Wilson Fellowships

<https://woodrow.org/fellowships/coursehero/>

Created by Course Hero and administered by the Woodrow Wilson Foundation, the Course Hero–Woodrow Wilson Fellowships were conceived as "genius grants" for tenure-track faculty who balance scholarly excellence and outstanding undergraduate teaching practices.

The newly expanded program will provide eight fellowships in the humanities/social sciences, life sciences, math/physical sciences, and business. Four fellowships will again be awarded to scholars working toward tenure, four fellowships will be awarded to instructors who are not in a tenure-track position. \$30,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 10, 2018

PAR-16-089 Imaging and Biomarkers for Early Detection of Aggressive Cancer (U01)

Letter of Intent Due Date(s) 30 days prior to the application due date (November 10, 2018).

Application Due Date(s) December 11, 2018, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. AIDS Application Due Date(s) Not Applicable.

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-089.html>

The purpose of this Funding Opportunity Announcement (FOA) is to: (i) invite researchers to submit collaborative research project (U01) applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies into a singular complementary approach, and (ii) establish a Consortium for Imaging and Biomarkers (CIB) to perform collaborative studies, exchange information, share knowledge and leverage common resources. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units. All Units are expected to participate in collaborative activities with other Units within the Consortium.

Over-diagnosis and false positives present significant clinical problems in the prevention, detection and treatment of cancer. Therefore, there is an unmet clinical need to more accurately identify early-stage aggressive cancers and distinguish lesions that are life threatening from those that are not. The specific objective of this FOA is to stimulate and support cancer imaging and biomarker research to develop, optimize, and clinically validate novel methods to:

- Detect aggressive cancers at the earliest stages possible;
- Reduce over-diagnosis;
- Reduce false positive tests; and
- Identify lethal cancers from non-lethal disease.

Deadline November 12, 2018

Cystic Fibrosis Research Inc. New - New Horizons Research Program

<http://cfri.org/research/funding-opportunities/>

The nationwide New Horizons Research Campaign funds promising new cystic fibrosis (CF) research projects in academic and hospital institutions. Supporting research of the highest scientific quality, the NH program also endeavors to fund those applications with the greatest relevance to finding improved treatments or a cure for CF. Priority is given to proposals of superior scientific quality. This funding opportunity is open to research institutions within the United States. The NH awards also provide seed funding for promising new lines of basic and clinical CF research that show prospects of future funding by other sources, such as the National Institutes of Health (NIH). \$140,000. Letter of Intent required.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 13, 2018

Chan Zuckerberg Initiative - Seed Networks for the Human Cell Atlas

<https://www.chanzuckerberg.com/science/rfa/seed-networks>

The Human Cell Atlas (HCA) is a global effort to create a reference map of all cell types in the human body. It is an ambitious goal to generate a fundamental reference for biomedical research. The HCA was born out of advances in single cell biology that made it conceivable to collect extensive measurements that inform our understanding of cellular heterogeneity in health and disease. Due to the growth of the community, pace of technology, and interest from the international community, the project has gone from conceivable to feasible. The Chan Zuckerberg Initiative and the Helmsley Charitable Trust are pleased to announce continued support for the Human Cell Atlas by collaborating on two new funding mechanisms that the community can access through a single application portal. The Chan Zuckerberg Initiative seeks to continue the work of the HCA community with a focus on interdisciplinary work and collaboration through the formation of 3 year Seed Networks. The Helmsley Charitable Trust welcomes applications that will construct a detailed atlas of the human gut. CZI Seed Networks aim to solidify growth of the community and result in a first draft of several organs – there is no requirement for a gut component in CZI applications. Additionally, newly formed Networks are designed to catalyze partnership among the scientific community and the funding community so that we can work together toward a first draft of the HCA. Award amount varies.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 14, 2018

Morris Animal Foundation Established Investigator Grants

[Established Investigator Grants](#)

The mission of Morris Animal Foundation (MAF) is to advance the science of animal health. Toward this aim, we are dedicated to funding hypothesis-driven and humane animal health research projects of high scientific merit and potential impact. Relevant projects promise to advance the health and well-being of companion animals and/or wildlife. The Established Investigator Grant is the most common grant, designed to provide funding for impactful research by individuals and teams with a previous record of research and publication.

There is no limit to the annual budget request, however the average award is approximately \$50,000.00/year. Maximum study duration is three years.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 14, 2018

Morris Animal Foundation First Award Grants

[First Award Grants](#)

The mission of Morris Animal Foundation (MAF) is to advance the science of animal health. Toward this aim, we are dedicated to funding hypothesis-driven and humane animal health research projects of high scientific merit and potential impact. The First Award Grant is designed to assist new faculty in establishing a successful research program.

First Award Funding is limited to two years at \$50,000 maximum per year (personnel and supplies), plus maximum of 8 percent indirect costs (maximum annual award \$54,000).

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 14, 2018

Morris Animal Foundation - Pilot Study

<https://www.morrisanimalfoundation.org/grants>

The Pilot Study Grant is designed to provide funding for innovative ideas to accelerate discovery and advance MAF's mission. Relevant projects promise to advance the health and well-being of companion animals and/or wildlife. Preliminary data are not required. \$10,800.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 14, 2018

The Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is inviting proposals for the latest round of the [Grand Challenges Explorations](#) initiative. Applications on the following six topics will be accepted until **Wednesday, November 14, 2018 11:30 am PST**:

- [Increasing Demand for Vaccination Services](#)
- [New Approaches for Manufacturing Gut Microbial Biotherapeutics](#)
- [Innovation for WASH in Urban Settings](#)
- [New Approaches for Strategic Prioritization of Agricultural Development Policies](#)
- [Tools and Technologies for Broad-Scale Pest and Disease Surveillance of Crop Plants in Low-Income Countries](#)
- [Innovations Driving Programmatic Performance in Immunization: Service Experience and Data Use + Measurement](#)

Deadline November 15, 2018 (LOI)

Cancer Research Institute Technology Impact Award

Technology Impact Award

A program designed to challenge the world's leading scientists and out-of-the box thinkers to create a research plan and assemble a research team that will develop a new technology platform with the potential to transform the field of cancer immunotherapy.

The Cancer Research Institute Technology Impact Award provides seed funding of up to \$200,000 to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 15, 2018

National Science Foundation 180576 Advanced Technologies and Instrumentation

Closing Date: November 15, 2018

The Advanced Technologies and Instrumentation (ATI) program provides individual investigator and collaborative research grants for development of new technologies and instrumentation for astronomy and astrophysics. The program supports overarching science objectives of the Division of Astronomical Sciences. Development of innovative, potentially transformative technologies are encouraged, even at high technical risk. Supported categories include but are not limited to: advanced technology development or concept feasibility studies and specialized instrumentation to enable new observations that are difficult or impossible to obtain with existing means. Proposals may include hardware and/or software development and/or analysis to enable new types of astronomical observations. The program encourages making products of research available to the public. It also encourages community coordination of technology and instrumentation development efforts via an annual Principal Investigators meeting.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 15, 2018

Medical Research Foundation (MRF) – Emergency Interim Support Grant

<http://www.ohsu.edu/xd/about/foundation/about/medical-research-foundation/grants.cfm>

Maximum grant award: \$40,000. Two to three grants awarded quarterly.

Application deadline dates: May 15, August 15, November 15.

Through this award, the MRF supports established investigators who are in need of bridge funding. The grant provides funding for research programs that have lost national grant funding, enabling investigators to develop data supporting application renewals. The application must contain a clear explanation of current grant funding and the status of grants in revision.

[EIS grant guidelines and application](#)

Deadline November 15, 2018

Medical Research Foundation (MRF) New Investigator Grant

<http://www.ohsu.edu/xd/about/foundation/about/medical-research-foundation/grants.cfm>

Maximum grant award: \$40,000. Two to three grants awarded quarterly.

Application deadline dates: May 15, August 15, November 15.

Through this award, the MRF supports promising new investigators in biomedical research. Principal investigators must be at the beginning of an independent career with a faculty position at one of Oregon's colleges or universities. A letter of support from the department chair or the institute director must accompany each application describing the independence of the principal investigator and the commitment of the unit to that investigator and their research program.

Deadline December 5, 2018

W81XWH-18-DMDRP-IIRA DoD Duchenne Muscular Dystrophy, Investigator-Initiated Research Award

<https://www.grants.gov/web/grants/search-grants.html>

The DMDRP Investigator-Initiated Research Award (IIRA) supports translational research that will accelerate the movement of promising ideas in Duchenne research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations with the specific goal of developing new therapies. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information between basic and clinical science. Within this continuum, the IIRA supports later-stage translational research projects, including early-phase, proof-of-principle clinical trials and correlative studies to better inform development of drugs, devices, and other interventions. Research projects may also include preclinical studies utilizing animal models, human subjects, or human anatomical substances.

Studies proposed under this award **should not include:**

- Target discovery
- Drug screening

Mechanism of action studies

For projects addressing “discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers,” a **biological marker**, or **biomarker**, is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention.¹ For the purpose of this award, **biomarker qualification** is defined as the evidentiary fit-for-purpose process of correlating a biomarker with the effects of an agent on biological processes and clinical endpoints.² Alternatively, **biomarker validation** refers to the process of ensuring that a biomarker or technology (e.g., imaging) will be accurately and reliably measured through the performance characteristics of a biomarker assay.³ The DMDRP encourages the study of biomarkers that can be detected through minimally invasive procedures (e.g., blood, urine, tissue, imaging). Examples of biomarkers may include signatures of genetic or epigenetic changes, specifically expressed genes, proteins, or metabolites, and molecular, physiological, and/or imaging entities, among others.

Optional Features: The IIRA mechanism allows for the inclusion of the following options, which would allow the applicant to request additional funds as described in Section II.D.5, Funding Restrictions. The Government reserves the right to fund an application at a lower funding level if it does not meet the eligibility criteria or intent of the optional feature(s).

Optional Interdisciplinary Collaborator (OIC): The FY18 DMDRP strongly encourages interdisciplinary collaborations between diverse groups of academic scientists, clinicians, industry scientists, the military Services, the Department of Veterans Affairs (VA), and other Federal Government agencies. The goal of the OIC is to bring new perspectives from other disciplines and/or bring new investigators into the Duchenne field that through their collaboration the team can undertake conceptually and technically novel approaches that would be less likely to succeed if undertaken by a more narrowly focused group of investigators. Some examples would include projects that establish interdisciplinary collaborations between, but not limited to, experimental biologists and immunologists, orthopaedists, or engineers.

Optional Nested Resident or Medical Student Traineeship: The intent of the Optional Nested Resident or Medical Student Traineeship is to provide mentored research opportunities in Duchenne. It is expected that the training will provide a valuable opportunity to develop the experience necessary to advance the trainee's research career in Duchenne. Only one traineeship may be requested per application. Plans for training and mentorship must be well developed and clearly described by the PI in Attachment 9: Statement of Traineeship. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

The anticipated direct costs budgeted for the entire period of performance for an FY18 DMDRP IIRA will not exceed **\$600,000** or **\$750,000** if applying for the IIRA with an OIC. Additional funding can be requested above the maximums specified for the IIRA or the IIRA with an OIC to specifically support the Optional Nested Resident or Medical Student Trainee. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

Deadline December 17, 2018

The Rita Allen Foundation and the American Pain Society 2019 Award in Pain

<http://americanpainsociety.org/funding-opportunities/grants/rita-allen-foundation-award-in-pain>

Guidelines for the Grant Application

Important dates:

Applications **open September 17, 2018, and close December 17, 2018**. Grant awards will be announced in March 2019 and funding disbursed for the initial twelve month grant period upon satisfactory execution of the grant agreement between the Rita Allen Foundation (RAF) and the grant recipient's institution.

About the Grant: The RAF and APS may award two grants for \$50,000 annually, for a period of up to three years to those research proposals demonstrating the greatest merit and potential for success. The committee will not provide a review of unsuccessful applications. The entire award is to be allocated to projects specifically chosen by the recipient. Overhead is not supported. Applications will be reviewed by a Scientific Advisory Committee of APS and RAF.

Research Topics Proposed research projects should be directed towards the molecular biology of pain and/or basic science topics related to the development of new analgesics for the management of pain due to terminal illness.

Eligibility

- Must have received committed start-up funds and independent laboratory space from their institution and this information must be clearly indicated in the Chair's letter of support for the candidate.
- Should be in the first three years of their appointment.
- Should be appointed to tenure track or equivalent position at their respective institution but not have received tenure at the time of the application.
- Must conduct the research and be appointed at an institution in the United States or Canada.
- Must indicate if an application has been submitted for another APS research award and the candidate may accept only one concurrent APS research award.
- A senior post-doc should not be an applicant.
- Associate professors should not be an applicant.

Grant Budget and Grantee Obligations:

- Eligible grant expenses may include Principal Investigator salary but not institutional overhead.
- Recipients are required to submit a 500-word annual progress report and a financial report to the RAF in accordance with the terms of the grant agreement.
- Investigators are required to present an abstract presentation of the sponsored research at the 2020 APS Scientific Meeting. Travel expense for attending the meeting must be included in the grant budget.

Deadline January 6, 2019

PAR-17-172 Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-172.html>

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) New Applications: February 7, 2019; and October 7, 2019.

Resubmission and Revision Applications: June 21, 2018, February 21, 2019, and October 21, 2019, by 5:00 PM local time of applicant organization. All **types of non-AIDS applications** allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) July 3, 2018; March 15, 2019; and November 4, 2019, by 5:00 PM local time of applicant organization. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on these dates.

Components of Participating Organizations National Center for Complementary and Integrative Health (NCCIH).

This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under **PAR-17-174**. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<http://www.nccih.nih.gov>). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Deadline January 6, 2019

PAR-17-174 Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3)

Letter of Intent Due Date(s) 30 days prior to the application due date (January 6, 2019).

Application Due Date(s) New Applications: February 7, 2019 and October 7, 2019.

Resubmission and Revision Applications: June 21, 2018, February 21, 2019, and October 21, 2019, by 5:00 PM local time of applicant organization. All **types of non-AIDS applications** allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) July 3, 2018; March 15, 2019; and November 4, 2019, by 5:00 PM local time of applicant organization. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-174.html>

Companion Funding Opportunity **PAR-17-172 U24 Resource-Related Research Projects – Cooperative Agreements**. **PAR-16-418, R61/R33 Exploratory/Developmental Phased Award**. **PAR-16-419, R33 Exploratory/Developmental Grants Phase II**. **PAR-17-216, U01 Research Project – Cooperative Agreements U01**. Number of Applications See **Section III. 3. Additional Information on Eligibility**.

This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated multi-site clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism.

In addition, an accompanying Data Coordinating Center application, submitted under **PAR-17-172**, proposing a data analysis and data management plan for the clinical project is required. **Both a Clinical Coordinating Center**

application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.

Deadline January 11, 2019

PAR-16-254 Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01)

Application Due Date(s) by 5:00 PM local time of applicant organization, January 11, 2019, by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s), by 5:00 PM local time of applicant organization; January 11, 2019, by 5:00 PM local time** of applicant organization. All types of [applications](#) allowed for this funding opportunity announcement are due on these dates.

Announcement Type New. Related Notices [May 27, 2016](#) - Notice of Change to Key Dates in PAR-16-254. See Notice [NOT-AI-16-054](#).

<http://grants.nih.gov/grants/guide/pa-files/PAR-16-254.html>

This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.

Deadline January 25, 2019

PAR-17-003 Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)

Letter of Intent Due Date(s) 30 days prior to the application due date (January 25, 2019).

Application Due Date(s) February 27, 2019; July 11, 2019; October 28, 2019, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

<http://grants.nih.gov/grants/guide/pa-files/PAR-17-003.html>

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention. Research applications may support acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Deadline January 25, 2019

PAR-16-322 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R24)

Application Due Date(s) Standard dates January 25, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s) apply by 5:00 PM local time** of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Announcement Type Reissue of [PAR-13-252](#). Related Notices None.

<https://grants.nih.gov/grants/guide/pa-files/PAR-16-322.html>

This FOA encourages applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

This FOA encourages applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The Division of Comparative Medicine (DCM) in ORIP and representatives from other NIH Institutes convened an NIH workshop in 2012 that addressed the current status of animal stem cell biology and made recommendations concerning improvements in technologies and applications of animal stem cells to regenerative medicine see

https://dpcpsi.nih.gov/sites/default/files/orip/document/summary_of_the_improving_animal_models.pdf.

The results of this workshop provide the basis for this FOA. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Background Information Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to damage or congenital defects. Regenerative medicine has the potential to solve the problem of the shortage of organs available for donation. It also holds the promise of repairing or replacing damaged tissues and organs in the body by stimulating organs previously considered irreparable to heal themselves. The recent discovery of the reprogramming of adult cells to a pluripotent state provides opportunities to address a major problem of regenerative medicine, immune rejection of transplanted tissue. The ability to generate differentiated cells and tissues using cells from specific patients will facilitate individualized medicine and eventually will lead to specialized therapies. The field is moving toward translation to clinical practice and is becoming increasingly dependent on animal models and information regarding the potential therapeutic efficacy of new technologies. Generating the correct type and quantity of the specific cell types required for replacement therapy is a significant challenge, as are the problems associated with introducing these cells into the proper environment in vivo and overcoming immune reactions. Finding solutions to these problems will require extensive testing in experimental animal models.

Major advances have been made in the past several years in deriving pluripotent cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) from both humans and animals. In parallel, other investigations have isolated and characterized multipotent “somatic” or “adult” stem cells from various tissues, including Mesenchymal Stem Cells (MSCs) and Germinal Stem Cells (GSCs). The discovery of mouse ESCs in 1981 revolutionized the field of developmental biology and provided new capability for genome manipulation and investigations of gene function. Isolation of human ESCs created new possibilities for the field of regenerative medicine. ES-like cells have been derived from a number of animal species, including rats, fish, cows, pigs and non-human primates. Many characteristics of animal ES-like cells, including surface markers, growth factor requirements, ability to differentiate and others can be quite different from human ESCs. There is a continuing expansion in the number and type of stem cells which potentially can be used for stem cell therapy.

The field of stem cell research experienced a dramatic new direction with the isolation of iPSCs, derived by reprogramming somatic cells to a pluripotent state. Several studies on various animal systems suggest that the basic pluripotency network appears to be conserved among different species, allowing derivation of iPSCs from a variety of animals. Significant efforts are needed to improve reprogramming methods to generate safer iPSCs with higher efficiency and better quality.

MSCs, a type of somatic stem cell, were originally identified as a subpopulation of bone marrow cells with osteogenic potential. The properties of MSCs have been examined extensively over the past decade. Studies using animal models have shown promising results following MSC therapy for induced injury in the musculoskeletal, cardiovascular, digestive and nervous systems. In addition, many clinical trials have been initiated to test the efficacy of MSC infusion for treating various human diseases. Given the wide range of tissue sources, the recognition of subpopulations with specific properties, and the frequent production of genomic alterations upon expansion in cell culture, extensive characterization of MSCs and development of

improved techniques are required. Most importantly, there is relatively limited understanding of the normal biological functions of MSCs and the mechanisms by which they participate in tissue repair.

GSCs are another type of somatic stem cell of great interest for regenerative medicine. They are an essential component of reproductive biology. Genetic manipulation of GSCs provides a powerful tool for producing transgenic animals, for elucidating mechanisms underlying germ cell development and differentiation and for understanding the interactions between stem cells and their niche. Further development of the methods for unlimited production of GSCs (for producing either sperm or eggs) will impact the ability to investigate the molecular basis of germ cell differentiation, explore the potential for germline stem cell therapy and treat infertility by transplantation. Numerous reports using animal and human GSCs have shown generation of pluripotent cells during in vitro cultivation, which potentially can solve a number of issues. However, it remains difficult to isolate, derive and maintain stable cultures of these cells from humans and model animal species. Furthermore, the mechanisms that determine the reprogramming of GSCs into pluripotent stem cells are not well understood and efficient methods for directed reprogramming of these still have to be developed.

Along with rodents, several other animal species are being developed as models for various studies in the field of regenerative medicine. Understanding the properties and capabilities of stem cells derived from animals such as fish, rabbits, dogs, pigs, sheep, goats and monkeys will increase the potential for the use of the most appropriate systems for modeling particular human disease conditions or for other medical applications. Non-rodent species, especially "large animal models" provide important advantages for transplantation studies, including large size, similarity to human physiology and pathology and longer life span, thus facilitating translation to studies in humans. The use of animal stem cells as a model for human cells in procedures related to regenerative medicine requires in-depth understanding of common regulatory pathways as well as species-specific properties and their impact on potential therapeutic applications.

Animal experiments have historically made a significant contribution to understanding human disease. However, animal studies need to be improved in order to increase reproducibility of the studies and better predict the effectiveness of treatment strategies in clinical trials. Several possible causes of the disparity between the results of animal studies and clinical trials have been identified, including failure to acknowledge the limitations of animal models, inadequate animal data, less than optimal disease models and overestimation of treatment efficacy due to the preferred publishing of positive results. These problems should be addressed in the design and execution of preclinical, animal-based studies involving stem cell based therapies.

Deadline January 26, 2019

RFA-HL-19-024 Short-Term Research Education Program to Increase Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)

Letter of Intent Due Date(s) 30 days prior to the application due date (January 26, 2019).

Application Due Date(s) February 26, 2019, September 10, 2019, February 26, 2020, September 10, 2020, February 26, 2021), by 5:00 PM local time of applicant organization.

All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) May 8, 2019, September 10, 2019, May 8, 2020, September 10, 2020, May 6, 2021, by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-024.html>

Announcement Type Reissue of [RFA-HL-16-008](#).

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences.

Deadline January 31, 2019

PA-17-055 NIH Summer Research Experiences for Students and Science Teachers (Admin Supp)

Current Closing Date for Applications: January 31, 2019.

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=290142>

The National Institutes of Environmental Health Sciences hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) with R01, R21, R15, R35, R37, or P01 awards that funds are available for administrative supplements to support summer research experiences in environmental health science for high school students, college undergraduates, masters degree candidates, medical students, secondary school science teachers, and science professors from R15/AREA grant eligible institutions. Administrative supplements must support work within the scope of the original project. Award amount not specified.

Deadline February 5, 2019

PAR-17-267 Modeling of Infectious Disease Agent Study Research Projects (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization.

AIDS Application Due Date(s) Standard AIDS dates apply by 5:00 PM local time of applicant organization.

All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-267.html>

The threat of emergence or re-emergence of infectious disease epidemics continues to be a concern of policymakers and the public health services. Better tools and methods are needed to improve our knowledge of the dynamics of emergence, surveillance and detection of events, and the effectiveness and implications of prevention and mitigation efforts. The variety of possible scenarios complicates the challenge of confronting these threats. An important role of science is to create a rational picture of the alternatives by collecting, analyzing, and interpreting relevant data and by developing models. The models themselves can guide the collection of further data. In addition, good models can reveal important patterns in the data which allow investigators to examine scenarios and to understand likely consequences of interventions. These capabilities can help responsible parties plan for and respond to an emerging epidemic or a bioterrorist threat.

The Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models can be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases. MIDAS has produced a number of software packages to help local, state and federal public health officials prepare for and respond to infectious disease emergencies. MIDAS trains public health officials in using modeling tools to understand how to prepare for and respond to infectious disease threats.

Information on current and previous MIDAS activities, publications, and reports can be found on the MIDAS website at <https://www.nigms.nih.gov/Research/specificareas/MIDAS/Pages/default.aspx>.

Deadline February 5, 2019

PA-18-725 Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date(s) Not Applicable.

Application Due Date(s) February 5, 2019, June 5, 2019, October 5, 2019 by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. AIDS Application

Due Date(s) Not Applicable.

[https://grants.nih.gov/grants/guide/pa-files/PA-18-](https://grants.nih.gov/grants/guide/pa-files/PA-18-725.html?utm_campaign=+31822883&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=)

[725.html?utm_campaign=+31822883&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=](https://grants.nih.gov/grants/guide/pa-files/PA-18-725.html?utm_campaign=+31822883&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=)

Announcement Type New. **Related Notices** None.

Companion Funding Opportunity [PA-18-724](#), [R21](#) Exploratory/Developmental Grant

The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Deadline February 5, 2019

PAR-16-093 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)

Application Due Date February 5, 2019, Standard dates apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) New Date per issuance of NOT-OD-16-069: Standard AIDS dates apply by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PAR-16-093.html>

This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Deadline February 5, 2019

PAR-16-228 Metabolic Reprogramming to Improve Immunotherapy (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

The first standard application due date for this FOA AIDS Application Due Date(s) [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

<https://grants.nih.gov/grants/guide/pa-files/PAR-16-093.html>

The overall goal of this funding opportunity announcement (FOA) is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses *in vivo*, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

Deadline February 5, 2019

PAR-17-244 Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)

Announcement Type Reissue of [PAR-16-058](#).

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-244.html>

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. AIDS Application Due Date(s) Not Applicable.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for collaborative R01 projects from multi-disciplinary teams to expand, improve, or transform the reliability and utility of mammalian cancer and tumor models for translational research. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for

cross-site coordination and communication. Collaborative studies are appropriate to address translational modeling research questions beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions.

With this FOA, the NCI intends to encourage submission of multidisciplinary projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, teams of applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

Deadline February 5, 2019

PAR-17-245 Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. AIDS Application Due Date(s) Not Applicable.

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-245.html>

Announcement Type Reissue of [PAR-16-059](#), Companion Funding Opportunity [PAR-17-244](#), Collaborative [R01](#) Grant. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

Deadline February 5, 2019

PA-17-283 Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)

Application Due Date February 5, 2019, apply by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Standard AIDS dates apply by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates.

Announcement Type New. Related Notices None.

Companion Funding Opportunity [PA-17-282 R21](#) Exploratory/Developmental Grant.

<https://grants.nih.gov/grants/guide/pa-files/PA-17-283.html>

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.

Deadline February 16, 2019

PAR-16-094 Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)

Application Due Date February 16, 2019 apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. AIDS Application Due Date(s): **New Date** per issuance of [NOT-OD-16-070: Standard AIDS dates apply by 5:00 PM local time of applicant organization](#). All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. <https://grants.nih.gov/grants/guide/pa-files/PAR-16-094.html>. Reissue of [PAR-13-115](#).

This FOA encourages Exploratory/Developmental Research grant (R21) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

Deadline February 16, 2019

PA-16-175 Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)

Application Due Date February 16, 2019 apply by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s) Standard AIDS dates** apply. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PA-16-175.html>

This funding opportunity announcement (FOA) invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. This FOA will utilize the exploratory/developmental research grant (R21) mechanism to foster cancer etiology and epidemiology research. While these studies may involve considerable risk, they may also lead to a breakthrough in a particular area, and to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, or clinical).

Deadline February 16, 2019

PA-17-282 Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21)

Application Due Date February 16, 2019, apply by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Standard AIDS dates, apply by 5:00 PM local time of applicant organization. All [types of applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/pa-files/PA-17-282.html>

The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. The goal will be to support research to identify and elucidate the pathogenic mechanisms underlying

the interactions among TB, T2DM (as well as pre-diabetes), and HIV, their role in immune dysregulation, and their impact on disease development, progression, and treatment outcomes. Understanding the basis of this dysregulation will allow identification and development of targeted therapies to improve treatment options among those with TB and T2DM with and without HIV. People living with HIV are well recognized to be at increased risk for developing TB, in large part due to the loss of CD4 T cells. However, even under anti-retroviral therapy treatment HIV+ individuals are still at an increased risk of developing active TB, as are individuals with T2DM. Chronic HIV infection is also associated with metabolic abnormalities such as insulin resistance, impaired glucose tolerance, and metabolic syndrome. The immunopathogenic effects of T2DM also result in significantly increased risk of TB activation and make TB therapy less effective, resulting in higher failure, relapse, and death rates. Additionally, pre-diabetes, where blood glucose levels are elevated but not to levels defined as T2DM, has also been reported to suppress immunity to TB, significantly increasing the risk of developing active TB. The mechanisms behind the increased risk of TB for T2DM and HIV co-infection, and their potential overlap, are yet to be fully elucidated. A chronic “metainflammatory” state, and immuno-metabolic dysregulation have been implicated. T2DM and HIV subvert essential immune cell functions for TB by dysregulating cell regulatory signaling pathway, often altering cellular metabolic activity.

Deadline April 30, 2019

PAR-17-173 Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)

Letter of Intent Due Date(s) 30 days prior to the application due date (April 30, 2019).

Application Due Date(s) New Applications: May 31, 2019; and January 31, 2020.

Resubmission and Revision Applications: June 14, 2019; and February 14, 2020 by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) March 2, 2018; October 31, 2018; June 28, 2019; and February 28, 2020; by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Components of Participating Organizations National Center for Complementary and Integrative Health (NCCIH).

<https://grants.nih.gov/grants/guide/pa-files/PAR-17-173.html>

This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under [PAR-17-175](#). The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<http://www.nccih.nih.gov>). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Deadline May 20, 2019

RFA-MH-18-200 NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01)

Letter of Intent Due Date(s) 30 days prior to the application due date May 20, 2018.

Application Due Date(s) June 20, 2018, June 20, 2019, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates.

AIDS Application Due Date(s) Not Applicable. Announcement Type Reissue of [RFA-MH-15-600](#).

<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-18-200.html>

The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the [NIMH Strategic Plan](#) and the [Research Domain Criteria \(RDoC\)](#) project.

Deadline May 20, 2019

RFA-MH-19-130 NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

Open Date (Earliest Submission Date) May 20, 2018.

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) June 20, 2018 and June 20, 2019, by 5:00 PM local time of applicant organization.

All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) Not Applicable.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-19-130.html>

Announcement Type Reissue of [RFA-MH-18-200](#).

The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the [NIMH Strategic Plan](#) and the [Research Domain Criteria \(RDoC\)](#) project.

Deadline June 4, 2019

RFA-HL-19-015 Physician-Scientist (PS) Research Award for Early Stage Investigators (ESIs) (R01 - Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-015.html>

Open Date (Earliest Submission Date) May 4, 2018.

Letter of Intent Due Date(s) 30 days before the application due date.

Application Due Date(s) June 4, 2018, June 4, 2019, June 4, 2020, by 5:00 PM local time of applicant organization.

All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) September 10, 2018, September 10, 2019, September 10, 2020, by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

The Physician-Scientist Research Award for Early Stage Investigators is intended to support the independence of physician-scientist faculty committed to academic careers in heart, lung, and blood diseases and sleep disorders (HLBS) research, and related implementation science.

Deadline June 25, 2019 LOI

RFA-DA-18-020 NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

Letter of Intent Due Date(s) June 25, 2019, 30 days prior to the application due date.

Application Due Date(s) July 25, 2019, July 25, 2020, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) September 7, 2019, September 7, 2020 by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Activity Code [UG3/UH3](#) Exploratory/Developmental Phased Award Cooperative Agreement

Announcement Type Reissue of [RFA-DA-18-003](#). **Related Notices** None.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-020.html>

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.

Deadline June 27, 2019

RFA-HG-18-002 Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)

Open Date (Earliest Submission Date) June 27, 2019.

Letter of Intent Due Date(s) 30 days prior to the application due date.

Application Due Date(s) June 27, 2019; June 26, 2020, by 5:00 PM local time of applicant organization. All [types of non-AIDS applications](#) allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s) September 10, 2018; September 10, 2019; September 10, 2020 by 5:00 PM local time of applicant organization. All [types of AIDS and AIDS-related applications](#) allowed for this funding opportunity announcement are due on these dates.

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-18-002.html>

This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than an order of magnitude) improvement in DNA sequencing, and practical methods for direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Deadline July 14, 2019

RFA-DA-18-019 NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)

Activity Code **DP1** NIH Director's Pioneer Award (NDPA). Announcement Type Reissue of [RFA-DA-18-001](#).

Letter of Intent Due Date(s) 30 days prior to the application due date (July 14, 2018).

Application Due Date(s) August 14, 2019; August 14, 2020), **by 5:00 PM local time** of applicant organization. All **types of applications** allowed for this funding opportunity announcement are due on these dates. **AIDS Application Due Date(s) August 14, 2019;** August 14, 2020 **by 5:00 PM local time** of applicant organization. All **types of AIDS and AIDS-related applications** allowed for this funding opportunity announcement are due on these dates.

The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term "avant-garde" is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>.

The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

Deadline July 16, 2019

PD-16-004Y Science of Learning

https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5567

Deadline(s) for applications: January 16, 2019, and July 10, 2019.

The Science of Learning program supports potentially transformative basic research to advance the science of learning. The goals of the SL Program are to develop basic theoretical insights and fundamental knowledge about learning principles, processes and constraints. Projects that are integrative and/or interdisciplinary may be especially valuable in moving basic understanding of learning forward but research with a single discipline or methodology is also appropriate if it addresses basic scientific questions in learning. The possibility of developing connections between proposed research and specific scientific, technological, educational, and workforce challenges will be considered as valuable broader impacts, but are not necessarily central to the intellectual merit of proposed research. The program will support research addressing learning in a wide range of domains at one or more levels of analysis including: molecular/cellular mechanisms; brain systems; cognitive affective, and behavioral processes; and social/cultural influences. The program supports a variety of methods including: experiments, field studies, surveys, secondary-data analyses, and modeling. Examples of general research questions within scope of the Science of Learning program include; How does learning transfer from one context to another or from one domain to another? How is learning generalized from specific experiences? What is the basis for robust learning that is resilient against potential interference from new experiences? How is learning consolidated and reconsolidated from transient experience to stable memory? How does the structure of the learning environment impact rate and efficacy of learning? For example, how do timing, content, learning context, developmental time point and type of engagement (e.g., active learning, group learning) impact learning processes and outcomes?; How can we integrate research findings and insights across levels of analysis, relating understanding of cellular and molecular mechanisms of learning in the neurons to circuit and systems-level computations of learning in the brain, to cognitive, affective, social, and behavioral processes of learning? What concepts, tools, or questions will provide the most productive linkages of across levels of analysis?; How can insights from biological learners contribute and derive new theoretic perspectives to computational learning systems, neuromorphic engineering, materials science, and nanotechnology? Biological and non-biological systems and social systems can all display learning. What can integration across these different domains contribute to a general understanding of learning? Award amount \$600,000.

Deadline LOI October 6, 2019

National Science Foundation – Advanced Informal STEM Learning (AISL) 17-573

LOI Intent deadline October 6, 2019 5pm pacific standard time. research.development@oregonstate.edu

[NSF Advanced Informal STEM Learning \(AISL\)](#)

Next due dates are: November 06, 2019.

NSF 17-573

NSF Advanced Informal STEM Learning (AISL) is now limited.

Note the changes: The number of proposals for which an organization may be the lead is limited to three (3); and The number of proposals for which one can be PI/Co-PI is limited to three (3); and The minimum one-year budget amount is \$75,000 for an organization in collaborative proposals uploaded as separate submissions from multiple organizations.

Interested - please email research.development@oregonstate.edu

At least 60 days prior to the Project/Program Start Date

Genentech Corporate Giving

<https://www.gene.com/good/giving/corporate-giving/imed>

We're proud to support the work of scientists, researchers, medical professionals and community-based organizations that are finding ways to help those in need and make a lasting, positive impact. Our charitable giving strategy focuses on three core objectives:

1. Advance Scientific Knowledge
2. Enhance Health Outcomes
3. Support Our Local Communities (Washington County)

Genentech provides funding for:

- ❖ Independent Medical Education
- ❖ [Healthcare-Related Charitable Support](#)
- ❖ Philanthropic Charitable Support
- ❖ Scientific Project Support
- ❖ Fellowships

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Rolling Deadline for Funding

E.W. "AI" Thrasher Award

<https://www.thrasherresearch.org/al-thrasher-award?lang=eng>

Ideal applications for the E.W. "AI" Thrasher Award address significant health problems that affect children in large numbers and offer the potential for practical solutions to these problems. Such solutions should be innovative and have the potential for broad applicability with low financial and/or technical barriers to implementation. Hypothesis-driven research is preferred over exploratory, hypothesis-generating research. Projects with a shorter distance to clinical applicability are given priority.

Principal Investigators must be qualified in terms of education and experience to conduct research. A doctoral-level degree is required. This award has a duration of up to three years and the median award amount is \$320,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Rolling Deadline for Funding

Patagonia World Trout Grants Program

The World Trout Initiative funds only groups and efforts working to restore and protect wild, self-sustainable trout, salmon and other fish species within their native range. This includes both indigenous freshwater and saltwater fish. We look for innovative groups that produce measurable results and work on long-term solutions to root causes of the problem. Proposed projects should be quantifiable, with specific goals, objectives and action plans, and should include measures for evaluating success. The funding range is typically between \$5,000 and \$15,000, depending on the specific needs of the project.

***OSU may submit only one proposal to Patagonia per year. If you are interested in applying, please contact Elizabeth Ocampo.**

Rolling LOI No Deadline Announcements for Funding

The G. Harold & Leila Y. Mathers Charitable Foundation Research Grants

<http://www.mathersfoundation.org/index.php/policies/>

The mission of the G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research and applying learnings and discoveries to benefit mankind. Basic scientific research, some with potential translational application, is central to this goal and fundamental to our operating principles.

Rolling LOI No Deadline Announcements for Funding

Simons Foundation - Targeted Grants in Mathematics and Physical Sciences

<https://www.simonsfoundation.org/grant/targeted-grants-in-mps/>

The Targeted Grant in MPS program provides funding for up to five years. The funding level and duration is flexible and should be appropriate based on the type of support requested in the proposal. The program is intended to support high-risk theoretical mathematics, physics and computer science projects of exceptional promise and scientific importance on a case-by-case basis.

No Deadline Announcements for Funding

FFAR – Rapid Outcomes from Agricultural Research (ROAR) **(\$150,000/year)**

Timeline: Ongoing Opportunity.

The Rapid Outcomes from Agricultural Research (ROAR) program, created by FFAR, provides nimble deployment of funds to support research and outreach in response to emerging or unanticipated threats to the nation's food supply or agricultural systems. ROAR participants, including but not limited to university researchers, farmers or producers, commodity groups and government officials, may apply for funds prior to an outbreak for development of diagnostics, monitoring and mitigation strategies, or enter into an agreement with FFAR that enables the quick release of funds should an outbreak occur. This funding opportunity will be open biannually for those groups wishing to apply to prepare for a pest or pathogen outbreak that is not already ongoing. Up to \$150,000 per one-year grant is available from FFAR, with the requirement that recipients provide equal or greater matching funds from non-U.S. federal sources.

Cycle 1 Posted Date: February 17, 2018. Responding to a Pest or Pathogen Outbreak

In the event of a pest or pathogen outbreak, submit a one-page concept note to FFAR outlining (1) the consortium members, including researchers, industry representatives and government officials, (2) the source and amount (up to \$150,000) of matching funds for the project and (3) a brief description of the pest or pathogen threat and why it should be considered for rapid funding. FFAR will use the concept note to decide whether or not to invite submission of a full application. This process is designed so that, if a qualifying emergency event occurs, the consortia may rapidly double their response budget (up to \$150,000).

Best approach for: Consortia who are in need of swift deployment of funding in response to a pest or pathogen outbreak.

Eligibility: *The following types of organizations are invited to apply:*

- Public and private institutions of higher education

- Nonprofit organizations
- For-profit organizations

Submit your concept note to Tim Kurt at tkurt@foundationfar.org. Meritorious concepts will be asked to submit a full proposal.

No Deadline Announcements for Funding

The G. Harold & Leila Y. Mathers Charitable Foundation

<http://www.mathersfoundation.org/index.php/policies/>

Life Sciences Research

The mission of the G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research and applying learnings and discoveries to benefit mankind. Basic scientific research, some with potential translational application, is central to this goal and fundamental to our operating principles. Invited proposals from young investigators whose research fits within the Foundation's overall mission will be considered.

Applications are initially reviewed by the Foundation's Executive Director, and subsequently, by the Foundation's Executive Committee. Applications may also be examined by outside reviewers. A response, in the form of approval, rejection, or request for additional information, may be expected within 90-120 days of the submission of the requested information.

No Deadline Announcements for Funding

National Science Foundation – 15-516 Earth Sciences: Instrumentation and Facilities (EAR/IF)

<http://www.nsf.gov/pubs/2015/nsf15516/nsf15516.htm>

15-516 (replaces 11-544).

Proposals Accepted Anytime.

The Instrumentation and Facilities Program in the Division of Earth Sciences (EAR/IF) supports meritorious requests for infrastructure that promotes research and education in areas supported by the Division ([see http://www.nsf.gov/div/index.jsp?div=EAR](http://www.nsf.gov/div/index.jsp?div=EAR)). EAR/IF will consider proposals for: (1) Acquisition or Upgrade of Research Equipment that will advance laboratory and field investigations and student research training opportunities in the Earth sciences. The **maximum request is \$750,000**. The **maximum request for upgrade of research group computing facilities is \$75,000**. (2) Development of New Instrumentation, Techniques or Software that will extend current research and research training capabilities in the Earth sciences. The maximum request is \$750,000. (3) Support of National or Regional Multi-User Facilities that will make complex and expensive instruments, systems of instruments or services broadly available to the Earth science research and student communities. (4) Support for Early Career Investigators to facilitate expedient development and operation of new research infrastructure proposed by the next generation of leaders in the Earth Sciences. The Early Career opportunity specifically allows for submission of a proposal for Acquisition or Upgrade of Research Equipment or Development of New Instrumentation, Techniques or Software which may include additional budget line items associated with support of a new full-time technician who will be dedicated to manage, operate and maintain the instrument(s) being requested. Any request for technical support under this opportunity is limited to three years' duration. The maximum total request is \$1,000,000.

No Deadline Announcements for Funding

Small Business Technology Transfer Program (STTR)

<http://www.sba.gov/offices/headquarters/oca/resources/6828>

STTR is an important small business program that expands funding opportunities in the federal innovation research and development arena. Central to the program is expansion of the public/private sector partnership to include the joint venture opportunities for small business and the nation's premier nonprofit research institutions. STTR's most important role is to foster the innovation necessary to meet the nation's scientific and technological challenges in the 21st century.

Competitive Opportunity for Small Business: STTR is a highly competitive program that reserves a specific percentage of federal R&D funding for award to small business and nonprofit research institution partners.

Small business has long been where innovation and innovators thrive. But the risk and expense of conducting serious R&D efforts can be beyond the means of many small businesses.

Conversely, nonprofit research laboratories are instrumental in developing high-tech innovations. But frequently, innovation is confined to the theoretical, not the practical. STTR combines the strengths of both entities by introducing entrepreneurial skills to high-tech research efforts. The technologies and products are transferred from the laboratory to the marketplace. The small business profits from the commercialization, which, in turn, stimulates the U.S. economy.

STTR Qualifications: Small businesses must meet certain eligibility criteria to participate in the STTR Program. American-owned and independently operated.

For-profit.

Principal researcher need not be employed by small business.

Company size limited to 500 employees.

(No size limit for nonprofit research institution).

The nonprofit research institution must also meet certain eligibility criteria.

Located in the US.

Meet one of three definitions.

Nonprofit college or university.

Domestic nonprofit research organization.

Federally funded R&D center (FFRDC).

The STTR System:

Each year, five federal departments and agencies are required by STTR to reserve a portion of their R&D funds for award to small business/nonprofit research institution partnerships.

Department of Defense.

Department of Energy.

Department of Health and Human Services.

National Aeronautics and Space Administration.

National Science Foundation.

These agencies designate R&D topics and accept proposals.

Three-Phase Program:

Following submission of proposals, agencies make STTR awards based on small business/nonprofit research institution qualification, degree of innovation, and future market potential. Small businesses that receive awards then begin a three-phase program.

Phase I is the startup phase. Awards of up to \$100,000 for approximately one year fund the exploration of the scientific, technical, and commercial feasibility of an idea or technology.

Phase II awards of up to \$750,000, for as long as two years, expand Phase I results. During this period, the R&D work is performed and the developer begins to consider commercial potential. Only Phase I award winners are considered for Phase II.

Phase III is the period during which Phase II innovation moves from the laboratory into the marketplace. No STTR funds support this phase. The small business must find funding in the private sector or other non-STTR federal agency funding.

SBA Role: The US Small Business Administration plays an important role as the coordinating agency for the STTR program. It helps the five agencies implement STTR, reviews their progress, and reports annually to Congress on its operation.

SBA is also the information link to STTR. SBA collects solicitation information from all the participating agencies and publishes it electronically in a Pre-Solicitation Announcement (PSA). The PSA is a single source for the topics and anticipated release and closing dates for each agency's solicitation(s).

For more information on the STTR Program, please contact:

**US Small Business Administration, Office of Technology, 409 Third Street, SW, Washington, DC 20416
(202) 205-6450**

All of SBA's programs and services are extended to the public on a nondiscriminatory basis.

No Deadline Announcements for Funding

Michelson Grants

To apply: <http://www.michelsonprizeandgrants.org/michelson-grants/apply> There is **no deadline** for submitting a letter of intent; they are accepted and reviewed on an ongoing basis. If the letter of intent is approved, the applicant will receive a deadline for a full proposal. Proposals must be submitted within two cycles of approval of the LOI.

[Apply for a Grant](#)

[Research Findings](#)

Quick Links

[Resources](#)

[FAQs](#)

[Scientific Advisory Board](#)

[About the Prize](#)

Found Animals offers **Michelson Grants of up to \$250,000 USD** per year for **up to three years of funding** for research in pursuit of a single-dose, permanent, nonsurgical sterilization product or technology for use in male and female dogs and cats.

As a mission-driven and product-focused program, the Michelson Prize & Grants funds research based on merit rather than a fixed approval rate. To date, we have approved over 30% of proposals submitted and have committed nearly \$14 million to 30+ approved projects across the globe.

No Deadline Announcements for Funding

The Collins Foundation

<http://www.collinsfoundation.org/submission-guidelines>

Eligibility Requirements: The Collins Foundation is committed to equal opportunity for all persons regardless of race, color, national origin, religion, sex, sexual orientation and gender identity, age, disability, or any other legally protected status. It is our intent to consider grant requests only from organizations and agencies that pursue these same principles in their governance, employment practices, and services. The Foundation recognizes that the issue of discrimination is more complex and nuanced than a single policy can convey. Requests may be considered from organizations that have convictions or beliefs of conscience that may not be entirely consistent with the Foundation's values around inclusion. However, organizations that require board members, employees, volunteers, or those receiving services to adhere to specific religious beliefs or lifestyles will automatically be subject to additional scrutiny for eligibility based on the assumption that such requirements are likely to be discriminatory and not compatible with the Foundation's policies or practices. Grant requests are considered only from organizations/agencies that have established their tax-exempt status under Section 501(c)(3) of the Internal Revenue Code and are not "private foundations" as defined under section 509(a) of the Code, or that have tax exemption as a governmental or other publicly-funded entity.

Grant requests are considered only from nonprofit organizations/agencies that have current registration with the offices of the Oregon State Attorney General and the Secretary of State.

Grants are made only for projects that directly benefit the residents of Oregon. Grants are not made to specific individuals.

Policy Guidelines: The Foundation will consider only one grant request from the same organization in a twelve month period, unless an additional request is invited by the Foundation.

The Foundation normally will not consider an additional grant request from an organization receiving a multi-year grant until twelve months following the final payment of the multi-year grant.

Grants normally are not made to elementary, secondary, or public higher education institutions; or to individual religious congregations. Grants normally are not made for development office personnel, annual fund-raising activities, endowments, operational deficits, financial emergencies, or debt retirement.

In considering applications for substantial projects, the Foundation prefers to participate with other donors, and encourages the applicant to seek support from other sources to share in the total project.

No Deadline Announcements for Funding

15-527 replaces 13-520 - NSF Research Coordination Networks (RCN)

General (non-targeted) RCN proposals accepted anytime.

<http://www.nsf.gov/pubs/2015/nsf15527/nsf15527.htm>

The goal of the RCN program is to advance a field or create new directions in research or education by supporting groups of investigators to communicate and coordinate their research, training and educational activities across disciplinary, organizational, geographic and international boundaries. RCN provides opportunities to foster new collaborations, including international partnerships, and address interdisciplinary topics. Innovative ideas for implementing novel networking strategies, collaborative technologies, and development of community standards for data and meta-data are especially encouraged. RCN awards are not meant to support existing networks; nor are they meant to support the activities of established collaborations. RCN awards do not support primary research. RCN supports the means by which investigators can share information and ideas, coordinate ongoing or planned research activities, foster synthesis and new collaborations, develop community standards, and in other ways advance science and education through communication and sharing of ideas. Award ceiling not specified.

No Deadline Announcements for Funding

The Cedar Tree Foundation Grants

Letters of Inquiry are accepted anytime.

Does not accept unsolicited proposals.

<http://www.cedartreefound.org/>

The Cedar Tree Foundation is a small family fund created by the late pediatrician and entrepreneur, Dr. David H. Smith. Dr. Smith believed in the power of individuals and organizations to make significant changes in our world, and we reflect that belief in our grant-making. The Cedar Tree Foundation's grant making focuses on the following areas of concern: (1) Sustainable Agriculture, (2) Environmental Education, & (3) Environmental Health. We give particular consideration to proposals that demonstrate strong elements of environmental justice, and conservation. We do not accept unsolicited proposals, but we welcome letters of inquiry for U.S. based work from non-profit organizations working within our program areas. Award ceiling: <\$10,000.

No Deadline Announcements for Funding

USFWS - 2017 National Fish Habitat Action Plan

<http://www.grants.gov/web/grants/view-opportunity.html?oppld=289987>

The National Fish Habitat Action Plan is a national investment strategy to leverage federal and privately raised funds to protect, restore, and enhance the nation's fish and aquatic habitats through partnerships that foster fish habitat conservation. Funds appropriated to the U.S. Fish and Wildlife Service's (Service) Fish and Aquatic Conservation (FAC) Program specifically to implement the Action Plan will be utilized in collaboration with the National Fish Habitat Board and Fish Habitat Partnerships. Fish Habitat Partnerships are the primary work units of the Action Plan, formed around distinct geographic areas, "keystone" fish species, or system types (e.g. large lakes, impoundments, estuaries). Funds will support national and regional science and coordination activities to protect, restore, or enhance fish habitats. All or a portion of project funds may be transferred to partner organizations if the Service lacks the capability to implement a project. Projects must protect, restore, or enhance fish and aquatic habitats or otherwise directly support habitat-related priorities of Fish Habitat Partnerships or the National Fish Habitat Board. Award amounts: \$5,000 - \$300,000. Applications are accepted on a rolling basis.

GRADUATE & UNDERGRADUATE STUDENT RESEARCH FUNDING

Deadline November 1, 2018

American Quarter Horse Foundation – Young Investigator Award

Specialized grant funding is available for MS and PhD level graduate students or DVM/VMD level residency interns. Investigators should be graduate or residency students who are currently enrolled in a graduate sciences program. Research performed should be monitored by a **graduate level advisor, major professor or senior faculty PhD or DVM/VMD mentor**. \$20,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact **Elizabeth Ocampo**, Foundation Relations Coordinator, if interested in applying.

Each year the Graduate School provides a number of awards to support outstanding graduate students and we are looking forward to seeing an amazing new group of scholars to award in 18-19.

Please read through nomination instructions carefully as some awards have been updated.

In addition, we have attached the 2018-2019 award matrix, which lists all award descriptions and deadlines as well as links to the web page and nomination form for each award. If you have any questions concerning the awards listed, please email Graduate.Scholarships@oregonstate.edu.

Due to the nature of the Travel Awards, those will continue to open and close per their cycle deadlines throughout the year. For your reference you can find the total list of awards below:

[Graduate Student Travel Award – Deadline November 1, 2018](#)

[P.F. and Nellie Buck Yerex Graduate Fellowship](#)

[Diversity Advancement Pipeline Fellowship](#)

[Graduate Diversity Recruitment Bonus](#)

[Thurgood Marshall Graduate Scholarship](#)

[Laurels Block Grant Program](#)

[Oregon Lottery Graduate Scholarship](#)

[Flyfisher's Club of Oregon Graduate Scholarship](#)

[Eric Englund Memorial Postgraduate Scholarship](#)

[Dr. Hari S. & Dr. Renuka R. Sethi Graduate Scholarship](#)

[Delson Bridge to the Future Fund](#)

[Jesse M. Bell Memorial Graduate Student Loan](#)

[Diversity Scholar Recruitment Award](#)

[Herbret F. Frolander Outstanding Graduate Teaching Assistant Award](#)

[Provost's Distinguished Graduate Fellowships and Scholarships](#)

POSTDOCTORAL RESEARCH FUNDING

Deadline November 1, 2018

American Quarter Horse Foundation – Young Investigator Award

Specialized grant funding is available for MS and PhD level graduate students or DVM/VMD level residency interns. Investigators should be graduate or residency students who are currently enrolled in a graduate sciences program. Research performed should be monitored by a **graduate level advisor, major professor or senior faculty PhD or DVM/VMD mentor**. \$20,000.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline November 14, 2018

Morris Animal Foundation Fellowship Training Grants

[Fellowship Training Grants](#)

The mission of Morris Animal Foundation (MAF) is to advance the science of animal health. Toward this aim, we are dedicated to funding hypothesis-driven and humane animal health research projects of high scientific merit and potential impact. The Fellowship Training Grant is designed to assist new investigators in launching a successful research career by providing salary support in a quality mentoring environment.

Fellowship training grant funding is limited to salary support only. A maximum of two years of salary up to \$50,000 per year (including benefits and indirect costs) is allowed. Tuition is not supported by this award.

The Office of Foundation Relations can provide proposal development and writing assistance for all opportunities. Please contact [Elizabeth Ocampo](#), Foundation Relations Coordinator, if interested in applying.

Deadline At least 60 days prior to the project/program start date

Genentech – Fellowships

<https://www.gene.com/good/giving/corporate-giving/fellowships>

Fellowships are for grants to independent professional organizations, independent charitable organizations, or other eligible institutions, where the funds are used to support advanced study by clinical and research professionals at an accredited university or teaching institution.

No Deadline Announcements for Funding

Cedar Tree Foundation Grants/David H. Smith Conservation Research Fellowship

<http://www.cedartreefound.org/smith.html>

The David H. Smith Conservation Research Fellowship, the nation's premier postdoctoral program in conservation biology, seeks to find solutions to the most pressing conservation challenges in the United States. The Smith Fellows program was established in 1998 by the late Dr. David H. Smith, founder of the Cedar Tree Foundation. Each Fellow's research is conducted in partnership with a major academic institution and an "on the ground" conservation organization, to help bridge the gap between theory and application. The Fellowship program is a collaboration of the Society for Conservation Biology and the Cedar Tree Foundation.

The Cedar Tree Foundation reviews LOIs four times a year (November, January, March, and June). You should hear from us within a month after your LOI was reviewed. If that time passes and you have not heard from us, please email or call. Additional Information about the Smith Fellows Program: [Smith Fellows Website](#).

Letters of inquiry should be no longer than three pages in length. In addition, please include an organizational budget, as well as a project budget if you are seeking project support. If you are applying for a grant of \$10,000 or less, please send an LOI that describes the problem you are addressing, your project plan, and your goals for the grant period. For all other grants, your 3 page LOI should address these questions:

1) What problems are you solving? 2) How are you addressing these problems? What proof do you have that this is an effective solution? 3) What does success look like? 4) How much money do you need? And how does this amount fit into your revenue strategy? 5) How will you measure and report progress? In lieu of answering these questions, you may attach your business plan.